Drug Approval | May 19, 2026
FDA expands Enhertu use in early HER2-positive breast cancer
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Baxfendy works in a fundamentally different way from current therapies
Access to genomic testing, not therapy cost, is the biggest challenge
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
